Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership.
D000818:Animals; D001549:Benzamides; D002869:Chromosome Aberrations / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D007668:Kidney / Q000187:drug effects / Q000201:enzymology; D007942:Leukemia, Experimental / Q000235:genetics*; D051379:Mice; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D017354:Point Mutation / Q000187:drug effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D013154:Spleen / Q000187:drug effects / Q000201:enzymology
D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl